Macrocyclic Factor VIIa Inhibitors Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current factor VIIa inhibitors have limitations in terms of pharmacological characteristics, including factor VIIa inhibitory activity, selectivity, dosage regimens, pharmaceutical properties, and potential for adverse side effects, necessitating the development of compounds with improved efficacy and safety profiles for treating thromboembolic disorders.
Innovation Solution
Development of novel macrocyclic compounds and their analogues, including stereoisomers, tautomers, pharmaceutically acceptable salts, and solvates, which serve as selective inhibitors of factor VIIa, offering enhanced inhibitory activity, selectivity, and improved pharmacokinetic properties to effectively treat thromboembolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current factor VIIa inhibitors are used, then thrombotic disorders can be treated, but pharmacological characteristics such as inhibitory activity, selectivity, and safety profile are limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of factor VIIa inhibitors through macrocyclization and specific substituent patterns (e.g., fluorinated phenyl groups, specific linker structures). These structural parameter changes result in improved inhibitory potency (lower IC50 values), enhanced selectivity for factor VIIa over other proteases, and reduced adverse side effects compared to previous linear inhibitors.
Solution Approach 2:
The patent employs composite material principles by creating macrocyclic compounds that integrate multiple functional groups and structural elements into a single molecular framework. The composite structure includes macrocyclic rings with specific substituents, linker groups, and aromatic moieties that work synergistically to achieve superior pharmacological properties including enhanced binding affinity and selectivity.
2Reliability
If higher dosages are used to improve efficacy, then inhibitory activity increases, but adverse side effects increase
Solution Approach 1:
The macrocyclic structure with optimized substituent parameters enables the compound to achieve high inhibitory activity at lower dosages. The structural modifications (macrocyclization, fluorinated groups, specific linker lengths) enhance binding affinity to factor VIIa, allowing effective inhibition with reduced drug exposure and consequently fewer adverse side effects.
3Reliability
If selectivity for factor VIIa is increased, then adverse side effects on other proteases are reduced, but compound structure becomes more complex
Solution Approach 1:
The patent achieves enhanced selectivity through precise parameter optimization of the macrocyclic structure, including specific substituent positions, linker configurations, and aromatic group arrangements. These targeted parameter changes create molecular features that specifically recognize and bind to factor VIIa while minimizing interactions with other proteases, thereby improving selectivity without requiring excessive structural complexity.
Data Source
AI summary
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.